LICENSE AGREEMENTLicense Agreement • May 12th, 2022 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 31st day of March, 2022 (the “Effective Date”), by and between SELLAS Life Sciences Group, Inc., a Delaware corporation with a principal place of business at Times Square Tower, 7 Times Square, Suite 2503, New York, NY, 10036, United States (“Sellas”) and GenFleet Therapeutics (Shanghai) Inc., a corporation organized and existing under the laws of China with offices at 1206 Zhangjiang Road, Suite A, Shanghai, China (“GenFleet”). Sellas and GenFleet may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
